-
Illumina Inc. (ILMN $99.17)
- $99.17 P/E (TTM): 12.79X Cap: $15.24B
- View ILMN Profile
- View Questions on ILMN
Detailed Quote
Questions on this company?
Become a Member
Company Profile
{tplLang.businessdescription | toLang tLang}
{ profileData.description }
{tplLang.details | toLang tLang}
{tplLang.ceo | toLang tLang}
{profileData.profile.details.ceo}
{tplLang.employees | toLang tLang}
{profileData.profile.details.employees | numeraljs '0,0'}
{tplLang.issuetype | toLang tLang}
{profileData.profile.details.issuetype | asIssueType}
{tplLang.industryclassifications | toLang tLang}
{tplLang.sector | toLang tLang}
{profileData.profile.classification.sector}
{tplLang.industry | toLang tLang}
{profileData.profile.classification.industry}
{tplLang.toolname| toLang tLang}
There is no {tplLang.toolname| toLang tLang} currently available for
{data.symbolstring}.
Interactive Chart
Key Ratios
Earnings
Analyst Recommendations
5i Recent Questions
-
Illumina Inc. (ILMN $99.17)
- $99.17 P/E (TTM): 12.79X Cap: $15.24B
- View ILMN Profile
- View Questions on ILMN
Q: Why is ILMN your favourite in Multiomic sequencing? And is this a good price point to start a position?
-
Illumina Inc. (ILMN $99.17)
- $99.17 P/E (TTM): 12.79X Cap: $15.24B
- View ILMN Profile
- View Questions on ILMN
-
Pacific Biosciences of California Inc. (PACB $1.33)
- $1.33 Cap: $399M
- View PACB Profile
- View Questions on PACB
-
CRISPR Therapeutics AG (CRSP $53.05)
- $53.05 Cap: $4.82B
- View CRSP Profile
- View Questions on CRSP
-
Bio-Techne Corp (TECH $54.33)
- $54.33 P/E (TTM): 67.73X Cap: $8.74B
- View TECH Profile
- View Questions on TECH
-
10x Genomics Inc. (TXG $14.28)
- $14.28 Cap: $1.74B
- View TXG Profile
- View Questions on TXG
Q: Can you recommend stocks or ETFs in Multiomic sequencing
-
Gilead Sciences Inc. (GILD $112.56)
- $112.56 P/E (TTM): 23.93X Cap: $139.66B
- View GILD Profile
- View Questions on GILD
-
Illumina Inc. (ILMN $99.17)
- $99.17 P/E (TTM): 12.79X Cap: $15.24B
- View ILMN Profile
- View Questions on ILMN
-
Intuitive Surgical Inc. (ISRG $473.84)
- $473.84 P/E (TTM): 65.62X Cap: $169.86B
- View ISRG Profile
- View Questions on ISRG
-
AbbVie Inc. (ABBV $207.92)
- $207.92 P/E (TTM): 88.91X Cap: $367.30B
- View ABBV Profile
- View Questions on ABBV
-
Eli Lilly and Company (LLY $731.96)
- $731.96 P/E (TTM): 59.74X Cap: $692.76B
- View LLY Profile
- View Questions on LLY
-
UnitedHealth Group Incorporated (DE) (UNH $302.29)
- $302.29 P/E (TTM): 12.72X Cap: $273.77B
- View UNH Profile
- View Questions on UNH
-
Novo Nordisk A/S (NVO $56.11)
- $56.11 P/E (TTM): 16.02X Cap: $363.68B
- View NVO Profile
- View Questions on NVO
-
BioMarin Pharmaceutical Inc. (BMRN $57.68)
- $57.68 P/E (TTM): 17.41X Cap: $11.26B
- View BMRN Profile
- View Questions on BMRN
Q: I am working on increasing my sector representation in Healthcare. I will shortly have filled a full position in ISRG, adding in this downturn. I have traded around UNH, and am planning to take it from a 1/2 to full position. I have 1/4 position in ILMN and do not think I should be topping it up; I perceive it to be risky. I need 2 more companies, or may need to take one or both of IRSG/UNH to more than a full position.
This provides me a surgical/instrumentation company and a service/product supplier. For diversity in the Healthcare space can you rank your preferred buys (with entry points) I'd appreciate 2 recommendations on the pharmaseuticals side and 2 on the biotech side, or as you may see that fits better.
While I am open US companies I do have a concern that the Trump administration will bring the DOGE and Executive Order train wrecks to health care. I would appreciate your views on this potential action and howe it may impact investment choice in the field.
Thanks as always,
Dave
This provides me a surgical/instrumentation company and a service/product supplier. For diversity in the Healthcare space can you rank your preferred buys (with entry points) I'd appreciate 2 recommendations on the pharmaseuticals side and 2 on the biotech side, or as you may see that fits better.
While I am open US companies I do have a concern that the Trump administration will bring the DOGE and Executive Order train wrecks to health care. I would appreciate your views on this potential action and howe it may impact investment choice in the field.
Thanks as always,
Dave
Insiders
Share Information
SEC Filings
News and Media